Sovremennaâ Revmatologiâ (2020-11-01)

Evaluation of the efficacy and safety of a combination of chondroitin sulfate and glucosamine sulfate for knee and hip osteoarthritis in real clinical practice

  • A. E. Karateev,
  • Yu. V. Barysheva,
  • Ya. V. Belokon,
  • T. Yu. Bolshakova,
  • Yu. Yu. Grabovetskaya,
  • E. A. Dolzhenkova,
  • L. N. Eliseeva,
  • O. B. Ershova,
  • E. V. Zonova,
  • I. Yu. Chernova,
  • A. O. Isakanova,
  • M. N. Kirpikova,
  • V. T. Komarov,
  • E. V. Kryukova,
  • A. I. Kulikov,
  • D. I. Lakhin,
  • L. A. Levasheva,
  • L. V. Masneva,
  • L. V. Menshikova,
  • Yu. V. Mishina,
  • S. V. Norina,
  • Yu. N. Pashkovsky,
  • A. V. Petrov,
  • A. G. Rusanov,
  • A. V. Sarapulova,
  • K. A. Svodtseva,
  • O. V. Semagina,
  • A. N. Sudakova,
  • S. N. Tkachenko,
  • M. M. Toporkov,
  • S. K. Tutelyan,
  • G. R. Fadienko,
  • O. S. Filonenko,
  • O. P. Fomina,
  • A. S. Chernov

DOI
https://doi.org/10.14412/1996-7012-2020-4-82-90
Journal volume & issue
Vol. 14, no. 4
pp. 82 – 90

Abstract

Read online

A combination of chondroitin and glucosamine is widely used in clinical practice as both a symptomatic and structure-modifying agent for the treatment of osteoarthritis (OA). The emergence of new drugs based on this combination substantially expands treatment options for OA therapy.Objective: to evaluate the efficacy and safety of Artroflex® that is a combination of chondroitin sulfate 400 mg and glucosamine sulfate 500 mg (CS + GS) to support joint health in patients with knee and/or hip OA.Patients and methods. When implementing an open observational research program, the results of using the CS + GS complex were assessed in 644 OA patients (74.7% women) (mean age, 58.0±14.6 years) who experienced moderate/severe pain and required to continuously take non-steroidal anti-inflammatory drugs (NSAIDs). The CS + GS complex was prescribed in a dose of 2 capsules per day for 3 months. The investigators estimated changes in pain on movement by a 0 to 10 verbal pain scale, general health (GH) by a 0–10 visual analogue scale), the Lequesne index, the need for NSAIDs, and patient satisfaction with treatment and its tolerance.Results and discussion. After 3-month therapy, there were decreases in pain intensity by 49.2±16.8%, GH scores by 45.6±18.1%, the Lequesne index from 9.0 [6.0; 13.0] to 5.0 [3.0; 9.0]; less than half (45.2%) of the patients still needed for NSAIDs. 82.2% of patients were satisfied or completely satisfied with treatment results; 89.6% reported good treatment tolerance.Adverse events (apparently associated with NSAID use) were recorded in 2.2% of cases. There were no serious complications that required CS + GS treatment discontinuation or hospitalization.Conclusion. The findings have indicated that Artroflex® used to support joint health is an effective agent that controls OA symptoms and has a good safety level.

Keywords